New product: Sunosi (solriamfetol) 75 and 150 mg film-coated tablets

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
22 January 2020

Abstract

Solriamfetol is licensed to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy (with/without cataplexy) or with obstructive sleep apnoea (OSA), whose EDS has not been satisfactorily treated by primary OSA therapy, such as CPAP.